Novartis: Hyperlipidemias trials

The registry lists 13 Hyperlipidemias studies with Novartis as lead sponsor. 4 are open to participants now and 3 have results posted.

Phase 1 2Phase 2 2Phase 3 7Phase 4 1No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Comparative Assessment of Inclisiran on Top of Standard of Care Versus Standard of Care Alone for LDL-C Evaluation in Acute Coronary Syndrome Patients in Saudi ArabiaNot yet recruitingNCT07684469Phase 4
• Evaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary SyndromesRecruitingNCT07102628Phase 3
• Study to Evaluate Efficacy and Safety of Inclisiran in Children With Heterozygous Familial HypercholesterolemiaRecruitingNCT06597019Phase 3
• Study to Evaluate Safety, Tolerability and Efficacy of Inclisiran in Children With Homozygous Familial HypercholesterolemiaRecruitingNCT06597006Phase 3
• A Randomized Study to Evaluate the Effect of an "Inclisiran First" Implementation Strategy Compared to Usual Care in Patients With Atherosclerotic Cardiovascular Disease and Elevated LDL-C Despite Receiving Maximally Tolerated Statin Therapy (VICTORION-INITIATE)CompletedNCT04929249Phase 3Results posted
• Management of LDL-cholesterol With Inclisiran + Usual Care Compared to Usual Care Alone in Participants With a Recent Acute Coronary SyndromeCompletedNCT04873934Phase 3Results posted
• Efficacy of LCQ908 on Cardiovascular RiskTerminatedNCT01474434Phase 2Results posted
• A Study of DII235 in Adults With Elevated Lipoprotein(a)Active, not recruitingNCT07235046Phase 2
• In Silico Study Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Patients With Established Cardiovascular DiseaseCompletedNCT05974345
• A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.Active, not recruitingNCT05739383Phase 3
• Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular DiseaseActive, not recruitingNCT05030428Phase 3
• Study of Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inclisiran in Chinese Participants With Elevated Serum LDL-CCompletedNCT04774003Phase 1
• Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TAP311 in Healthy Subjects and Dyslipidemic PatientsCompletedNCT01487460Phase 1